[go: up one dir, main page]

ATE304528T1 - Verbindungen mit wachstumshormon-freisetzenden eigenschaften - Google Patents

Verbindungen mit wachstumshormon-freisetzenden eigenschaften

Info

Publication number
ATE304528T1
ATE304528T1 AT01123155T AT01123155T ATE304528T1 AT E304528 T1 ATE304528 T1 AT E304528T1 AT 01123155 T AT01123155 T AT 01123155T AT 01123155 T AT01123155 T AT 01123155T AT E304528 T1 ATE304528 T1 AT E304528T1
Authority
AT
Austria
Prior art keywords
compounds
growth hormone
hormone releasing
releasing properties
formula
Prior art date
Application number
AT01123155T
Other languages
German (de)
English (en)
Inventor
Bernd Peschke
Michael Ankersen
Thomas Kruse Hansen
Henning Thoegersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE304528T1 publication Critical patent/ATE304528T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06Compounds containing any of the groups, e.g. semicarbazides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01123155T 1996-07-22 1997-07-17 Verbindungen mit wachstumshormon-freisetzenden eigenschaften ATE304528T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK80396 1996-07-22

Publications (1)

Publication Number Publication Date
ATE304528T1 true ATE304528T1 (de) 2005-09-15

Family

ID=8097747

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97930368T ATE218537T1 (de) 1996-07-22 1997-07-17 Verbindungen mit wachstumshormon freisetzenden eigenschaften
AT01123155T ATE304528T1 (de) 1996-07-22 1997-07-17 Verbindungen mit wachstumshormon-freisetzenden eigenschaften

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT97930368T ATE218537T1 (de) 1996-07-22 1997-07-17 Verbindungen mit wachstumshormon freisetzenden eigenschaften

Country Status (8)

Country Link
US (3) US5922770A (fr)
EP (2) EP0923539B1 (fr)
JP (1) JP4425992B2 (fr)
AT (2) ATE218537T1 (fr)
AU (1) AU3434697A (fr)
DE (2) DE69713109T2 (fr)
WO (1) WO1998003473A1 (fr)
ZA (1) ZA976371B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058950A1 (fr) * 1997-06-20 1998-12-30 Novo Nordisk A/S Composes ayant des proprietes de liberation de l'hormone de croissance
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
PL194560B1 (pl) * 1998-05-11 2007-06-29 Novo Nordisk As Związki o właściwościach uwalniania hormonu wzrostu, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie
TW450954B (en) * 1998-05-14 2001-08-21 Pharmacia & Amp Upjohn Company Phenylsulfonamide-phenylethylamines useful as dopamine receptors
DE69943239D1 (de) * 1998-06-30 2011-04-14 Novo Nordisk As Verbindungen mit wachstumshormon-freisetzenden eigenschaften
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
CN1157224C (zh) 1999-02-18 2004-07-14 科研制药株式会社 用作生长激素促分泌剂的新酰胺衍生物
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
CA2401749A1 (fr) * 2000-03-23 2001-09-27 Elan Pharmaceuticals, Inc. Composes et methodes de traitement de la maladie d'alzheimer
US6613801B2 (en) * 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
EP1159964B1 (fr) 2000-05-31 2009-10-28 Pfizer Products Inc. Utilisation de secrétagogues d'hormones de croissance pour stimuler la motilité gastrointestinale
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
EP1666452A2 (fr) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Composés pour le traitement de la maladie d'Alzheimer
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
DE60116313T2 (de) 2000-06-30 2006-08-31 Elan Pharmaceuticals, Inc., San Francisco Verbindungen zur behandlung der alzheimerischen krankheit
SI1368336T1 (sl) * 2001-02-16 2006-10-31 Allelix Neuroscience Inc S tiofenom substituirani aminski derivati kot inhibitorji glyt-1
CA2440042C (fr) * 2001-03-05 2011-09-27 Transtech Pharma, Inc. Derives de carboxamide utilises comme agents therapeutiques
JP2004523565A (ja) * 2001-03-05 2004-08-05 トランス テック ファーマ,インコーポレイテッド 治療因子としてのベンゾイミダゾール誘導体
EP1401452A1 (fr) * 2001-06-27 2004-03-31 Elan Pharmaceuticals, Inc. Derives de beta-hydroxyamine utiles dans le traitement de la maladie d'alzheimer
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
SI1471054T1 (sl) * 2002-01-11 2009-12-31 Daiichi Sankyo Co Ltd Amino alkoholni derivati ali derivati fosfoniäśne kisline in medicinski sestavki, ki vsebujejo le-te
US7230133B2 (en) 2003-05-01 2007-06-12 Bristol-Myers Squibb Company Malonamides and malonamide derivatives as modulators of chemokine receptor activity
MXPA05012350A (es) * 2003-05-20 2006-05-25 Transtech Pharma Inc Antagonistas rage como agentes para la amiloidosis inversa y enfermedades asociadas con la misma.
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005027913A1 (fr) * 2003-09-19 2005-03-31 Pfizer Products Inc. Compositions pharmaceutiques et methodes de traitement consistant en des associations d'un derive de la 2-alkylidene-19-nor-vitamine d et d'un secretagogue de l'hormone de croissance
CA2557536C (fr) 2004-02-24 2010-07-13 Sankyo Company Limited Compose d'alcool amine
CA2565324A1 (fr) * 2004-03-30 2005-10-20 Sapphire Therapeutics, Inc. Procede de reduction de la proteine c-reactive a l'aide de secretagogues de l'hormone de croissance
EP1768976B1 (fr) * 2004-06-29 2017-04-26 Helsinn Healthcare S.A. Formes cristallines d'acide (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylique 1,2,2-trimethylhydrazide
ES2388501T3 (es) * 2004-08-12 2012-10-16 Helsinn Healthcare S.A. Uso de secretagogos de la hormona de crecimiento para estimular la motilidad del sistema gastrointestinal
EP1942193A4 (fr) 2005-08-25 2010-10-27 Ube Industries PROCÉDÉ DE PRODUCTION D ACIDE (S OU R)-a -AMINÉ OPTIQUEMENT ACTIF OU D ESTER D ACIDE (S OU R)-a-AMINÉ OPTIQUEMENT ACTIF
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
ES2558928T3 (es) 2007-01-31 2016-02-09 Dana-Farber Cancer Institute, Inc. Péptidos p53 estabilizados y usos de los mismos
WO2008130464A1 (fr) 2007-02-09 2008-10-30 Tranzyme Pharma, Inc. Modulateurs macrocycliques du récepteur de la ghréline et leurs procédés d'utilisation
EA200970764A1 (ru) * 2007-02-13 2010-04-30 ХЕЛСИНН ТЕРАПЬЮТИКС (Ю. Эс.), ИНК. Способ лечения расстройств, вызванных пролиферацией клеток, с применением стимуляторов секреции гормона роста
BRPI0809366B8 (pt) 2007-03-28 2021-05-25 Harvard College polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
UA105657C2 (uk) 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
TWI517850B (zh) 2009-09-30 2016-01-21 Vtv治療有限責任公司 經取代之咪唑衍生物及其使用方法
CA2807685C (fr) 2010-08-13 2020-10-06 Aileron Therapeutics, Inc. Macrocycle peptidomimetique derive de p53
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
CN108912211A (zh) 2012-02-15 2018-11-30 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
WO2014071241A1 (fr) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Acides aminés disubstitués et procédés de préparation et d'utilisation de ceux-ci
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
EP3197478A4 (fr) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leurs utilisations
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
EP3916817B1 (fr) 2016-02-09 2024-09-18 Lumeova, Inc Dispositifs et systèmes de communication à haute vitesse, sans fil, à très large bande
WO2019190822A1 (fr) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Formes cristallines de [3-(4- {2-butyl-1-[4-(4-chloro-phénoxy)-phényl]-1h-imidazol-4-yl} -phénoxy)-propyl]-diéthyl-amine
WO2019190823A1 (fr) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Sels pharmaceutiquement acceptables de [3-(4- {2-butyl-1-[4-(4-chlorophénoxy)-phényl]-1h-imidazol-4-yl} -phénoxy)-propyl]-diéthyl-amine
WO2020076668A1 (fr) 2018-10-10 2020-04-16 Vtv Therapeutics Llc Métabolites de [3-(4-{2-butyl-1-[4-(4-chloro-phénoxy)-phényl]-1h-imidazol-4-yl}-phénoxy)-propyl]-diéthyl-amine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT736039E (pt) * 1993-12-23 2001-04-30 Novo Nordisk As Compostos com propriedades para liberar a hormona de crescimento
IL116923A (en) * 1995-01-27 2000-09-28 Novo Nordisk As Compounds with growth hormone releasing properties and pharmaceutical compositions containing them
ES2323159T3 (es) * 1995-12-22 2009-07-07 Novo Nordisk A/S Compuestos con propiedades de liberacion de la hormona del crecimiento.

Also Published As

Publication number Publication date
ZA976371B (en) 1998-01-22
DE69734215T2 (de) 2006-06-29
JP4425992B2 (ja) 2010-03-03
DE69713109D1 (de) 2002-07-11
WO1998003473A1 (fr) 1998-01-29
EP1184370A2 (fr) 2002-03-06
ATE218537T1 (de) 2002-06-15
US5922770A (en) 1999-07-13
EP1184370A3 (fr) 2002-03-27
DE69713109T2 (de) 2003-01-02
US6127354A (en) 2000-10-03
JP2000515517A (ja) 2000-11-21
EP1184370B1 (fr) 2005-09-14
EP0923539B1 (fr) 2002-06-05
US6274584B1 (en) 2001-08-14
EP0923539A1 (fr) 1999-06-23
AU3434697A (en) 1998-02-10
DE69734215D1 (de) 2005-10-20

Similar Documents

Publication Publication Date Title
ATE304528T1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
MY113488A (en) Compounds with growth hormone releasing properties
RU94016393A (ru) Пептиды, обладающие способностью к стимулированию высвобождения гормона роста, способ получения, фармацевтическая композиция, способ лечения
ATE69376T1 (de) Haarwuchsmittel.
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
DE69333607D1 (de) Vorrichtung zur Herstellung von vorgefüllten, sterilen Abgabevorrichtungen
ATE271874T1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
DK0740650T3 (da) Codrugs som metode til styret transport af lægemiddel
SE9401406L (sv) Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma
IT8619055A0 (it) Composizioni farmaceutiche comprendenti peptidi del gruppo colecistochinina-cerulina per il trattamento terapeutico degli statidi shock e dell'insufficienza respiratoria e cardiocircolatoria.
DK0562705T3 (da) Anvendelse af L-deprenyl til fremstilling af et lægemiddel til behandling af Cushings sygdom
DE69716223D1 (de) Vorrichtung zur Herstellung von medizinischen Pflastern zur perkutanen Verabreichung
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
GR3019774T3 (en) Piperidylmethyl substituted chroman derivatives as agents for the treatment of diseases of the central nervous system
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
GR3032224T3 (en) Therapeutic agent for threatened abortion.
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
NO166280C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n,n'-disubstituerte ureaer.
FI102810B1 (fi) Aine eläimen ihon käsittelyyn
RU2001113054A (ru) Способ лечения послеродового острого гнойно-катарального эндометрита коров
AP1629A (en) Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes.
WO2001068693A8 (fr) Nouveau polypeptide, proteine humaine de reception cannabinoide 7, et polynucleotide codant pour ce polypeptide
RU2001123759A (ru) Способ лечения одонтогенного остеомиелита, осложненного флегмоной
FI935575A7 (fi) 3-(kinolin-6-yylimetyyli)-4H-imidatsol-4-onijohdannaisia, menetelmä niiden valmistamiseksi ja niiden terapeuttinen käyttö

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties